Eroglu Z, Kim Y, Gibney G, et al. Mature results of combination nivolumab (NIVO) plus ipilimumab (IPI) as adjuvant therapy in stage IIIC/IV melanoma (MEL). SMR 2017, abstract SMR09-06.
Nieuwe hoogleraar wil immuuntherapie voor melanomen personaliseren
nov 2020 | Dermato-oncologie, Immuuntherapie